
---
title: Antiparkinsons - INICET High Yield
markmap:
  colorFreezeLevel: 6
---

## Antiparkinsons Drugs (INICET High Yield)

### Levodopa + Carbidopa/Benserazide
- **Mechanism:** Levodopa converted to Dopamine; Carbidopa/Benserazide inhibit peripheral decarboxylase
- **Key Drug:** Levodopa-Carbidopa (Synergistic)
- **Use:** Most effective for motor symptoms, particularly bradykinesia & rigidity. Gold standard.
- **Side Effects:**
  - **Motor:** Wearing off, On-off phenomenon, Dyskinesias (peak dose)
  - **Psychiatric:** Hallucinations, Delusions, Confusion, Psychosis
  - **Cardiovascular:** Orthostatic Hypotension, Arrhythmias
  - **Other:** Nausea/Vomiting (reduced by Carbidopa), Brown/Red urine/sweat/saliva
- **INICET Buzz:** Wearing off, On-off, Dyskinesias, Protein interaction (take on empty stomach), Pyridoxine (Vit B6) interaction (less with Carbidopa)

### COMT Inhibitors
- **Mechanism:** Inhibit Catechol-O-Methyl Transferase, reducing Levodopa breakdown peripherally & centrally.
- **Key Drugs:**
  - **Entacapone:** Peripheral acting. **Buzz:** Used *only* with Levodopa, Yellow/Orange urine
  - **Tolcapone:** Peripheral & Central acting. **Buzz:** Hepatotoxicity risk (requires monitoring), Diarrhea
- **Use:** Adjunct to Levodopa to extend its half-life and reduce wearing off.
- **Side Effects:** Diarrhea (common with Entacapone), Dyskinesias (increased due to more available Levodopa), Nausea, Orthostatic Hypotension, Hallucinations, Hepatic failure (Tolcapone)

### MAO-B Inhibitors
- **Mechanism:** Inhibit Monoamine Oxidase B, preventing central dopamine breakdown.
- **Key Drugs:**
  - **Selegiline:** Irreversible. Metabolites include amphetamine/methamphetamine (**Buzz:** Insomnia)
  - **Rasagiline:** Irreversible. More potent, no amphetamine metabolites.
  - **Safinamide:** Reversible, also modulates glutamate release.
- **Use:** Early monotherapy, or adjunct to Levodopa to reduce wearing off.
- **Side Effects:** Insomnia (Selegiline), Nausea, Orthostatic Hypotension, Hallucinations. **Buzz:** Serotonin Syndrome risk (with SSRIs, SNRIs, TCAs), Hypertensive crisis risk (with tyramine foods - less with Rasagiline)

### Dopamine Agonists
- **Mechanism:** Directly stimulate dopamine receptors (D2, D3).
- **Key Drugs:**
  - **Non-Ergot:** Pramipexole (D3 > D2), Ropinirole (D2 > D3), Rotigotine (patch), Apomorphine (injectable, rescue)
  - **Ergot:** Bromocriptine, Pergoline (Less used due to valvular fibrosis risk)
- **Use:** Early monotherapy (delay Levodopa), Adjunct to Levodopa (reduce dose/fluctuations). **Buzz:** Preferred in younger patients.
- **Side Effects:**
  - **Common:** Nausea, Vomiting, Orthostatic Hypotension, Peripheral Edema, Somnolence (Sudden sleep attacks - **Buzz**), Hallucinations, Confusion, Dyskinesias (less than Levodopa).
  - **Specific:** Impulse Control Disorders (Gambling, Hypersexuality, Shopping - **Buzz**), Fibrotic reactions (ergots), Injection site reactions (Apomorphine), Nausea/Vomiting (Apomorphine - requires antiemetic like Domperidone).

### Anticholinergics
- **Mechanism:** Block muscarinic receptors, reducing cholinergic overactivity.
- **Key Drugs:** Benztropine, Trihexyphenidyl
- **Use:** Primarily for tremor, especially in younger patients with minimal bradykinesia/rigidity.
- **Side Effects:** Anticholinergic effects (Dry mouth, Blurred vision, Urinary retention, Constipation), Cognitive impairment, Confusion, Hallucinations. **Buzz:** Avoid in elderly (cognitive side effects).

### Amantadine
- **Mechanism:** NMDA receptor antagonist, also enhances dopamine release/inhibits reuptake.
- **Use:** Mild symptoms, particularly tremor. **Buzz:** Levodopa-induced dyskinesia.
- **Side Effects:** Livedo reticularis, Peripheral edema, Confusion, Hallucinations, Dry mouth.

### Other Agents
- **Istradefylline:** Adenosine A2A receptor antagonist. **Use:** Adjunct to Levodopa for wearing off.

### Management of Motor Complications
- **Wearing Off:** Increase Levodopa frequency, add COMT-I, MAO-B-I, or Dopamine Agonist.
- **On-Off:** Add COMT-I or MAO-B-I, switch to controlled-release Levodopa, use Apomorphine (rescue).
- **Dyskinesias:** Reduce Levodopa dose, add Amantadine, switch to Dopamine Agonist (less dyskinesia risk).

### INICET Buzz Words
- **Wearing off:** End-of-dose deterioration
- **On-off phenomenon:** Sudden fluctuations in motor state
- **Dyskinesias:** Involuntary movements (peak-dose most common)
- **Impulse control disorders:** Dopamine agonists, especially Pramipexole/Ropinirole
- **Sudden sleep attacks:** Dopamine agonists
- **Livedo Reticularis:** Amantadine
- **Hepatotoxicity:** Tolcapone
- **Diarrhea:** Entacapone, Tolcapone
- **Yellow/Orange Urine:** Entacapone
- **Serotonin Syndrome:** MAO-B Inhibitors + Serotonergic drugs
- **Avoid in Elderly:** Anticholinergics
- **Levodopa-induced dyskinesia treatment:** Amantadine
- **Rescue therapy:** Apomorphine
- **Protein Interaction:** Levodopa absorption affected by protein
